Archive Newsletter
-
08.25.26 -- Reimagine Solid Tumor Immunotherapy With SRC-3-Edited Tregs
8/25/2026
08/25/26 Cell & Gene Newsletter
-
08.24.26 -- The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
8/24/2026
08/24/26 Cell & Gene Newsletter
-
08.21.26 -- Smarter Workflows For Cell & Gene Production
8/21/2026
08/21/26 Cell & Gene Newsletter
-
08.21.26 -- Rewriting The Playbook For Stargardt Disease With Shannon Boye, Ph.D.
8/21/2026
08/21/26 Cell & Gene Newsletter
-
08.20.26 -- Are Biopharma Companies Outsourcing Their Ability To Think?
8/20/2026
08/20/26 Cell & Gene Newsletter
-
08.19.26 -- Building A More Scalable Gene Therapy Program
8/19/2026
08/19/26 Cell & Gene Newsletter
-
08.19.26 -- Scaling Human-Relevant Science For Biologics Development
8/19/2026
08/19/26 Cell & Gene Newsletter
-
08.19.26 -- Redefining Autoimmune Treatment Via Antigen-Specific Immune Tolerance
8/19/2026
08/19/26 Cell & Gene Newsletter
-
08.18.26 -- The Missing Link Between AI Pilots And Production Success
8/18/2026
08/18/26 Cell & Gene Newsletter
-
08.18.26 -- Building Platform Strategies Instead Of One Off Vector Solutions
8/18/2026
08/18/26 Cell & Gene Newsletter